Market research
R3I1.F Advanced Oncotherapy plc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.05
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- GB00BD6SX109
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.05
About
About Advanced Oncotherapy plc
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.
Research context
Advanced Oncotherapy plc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the R3I1.F discussion.
5 years, 7 months ago
Advanced Oncotherapy plc is currently in a long term downtrend where the price is trading 6.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Advanced Oncotherapy plc gets an overall score of 1/5.